iOnctura
Developing precision small molecules to combat hard-to-treat tumors.
28 employees · est. 2017 · Geneve, Switzerland
Pharvaris is the older company (2017 vs 2015); Pharvaris is the larger of the two.
Side-by-Side Comparison
| Metric | iOnctura | Pharvaris |
|---|---|---|
| Founded | ||
| Founded | 2017 | 2015 older |
| Headquarters | ||
| Headquarters | Geneve, Switzerland | Zug, Switzerland |
| Employees | ||
| Employees | 28 | 139 larger |
| Industry | ||
| Industry | Biotechnology, Health Care, Medical Devices | Biotechnology, Health Care, Life Sciences |
| Funding Stage | ||
| Funding Stage | Series B | IPO |
| Total Funding | ||
| Total Funding | $118.37M | $967.33M |
| Funding Rounds | ||
| Funding Rounds | 9 | 8 |
| Services | ||
| Services | Not tracked yet | Development of oral bradykinin B2 receptor antagonists, Research and clinical trials for hereditary and acquired angioedema, Providing oral alternatives to traditional injection therapies |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with hereditary angioedema (HAE), Patients with acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), Healthcare providers managing bradykinin-mediated conditions |
| Taxonomy | ||
| Taxonomy | Biotech, Cancer Therapy, Drug Development, Clinical-stage, Cancer Treatment, PI3Kδ Inhibitor, Autotaxin Inhibitor, Tumor Survival Pathways, Immunotherapy, Precision Medicine, Oncology, Investors, Clinical Trial, Innovation, Targeted Therapy | Clinical-stage Biotechnology, Bradykinin-B2-Receptor Antagonists, Oral Therapeutics Development, Rare Disorders, Hereditary Angioedema, Small Molecule Drug Discovery, Pharmaceutical Development, Novel Therapeutics, Phase 1 Clinical Trials, Drug Candidate Development, Innovative Medicine, Receptor-mediated Diseases, Non-injectable Therapies, Biotech Leadership |
| Website | ||
| Website | ionctura.com | pharvaris.com |
About iOnctura
iOnctura is a Swiss-based biopharmaceutical company founded in 2017. The company is dedicated to developing precision small molecules to combat neglected and hard-to-treat cancers. Their innovative treatments, including roginolisib and cambritaxestat, have entered mid-stage clinical development, off...
About Pharvaris
Pharvaris, founded in 2015, is a Switzerland-based clinical-stage company at the forefront of developing oral treatments for bradykinin-mediated diseases such as hereditary angioedema (HAE). The company’s slogan, "Pioneering science for patient choice", reflects its dedication to innovative therapeu...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at iOnctura and Pharvaris — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at iOnctura and Pharvaris — by email.
Frequently Asked Questions
Compare iOnctura with someone else
Start typing a company name or domain.